OBJECTIVE: To assess the efficacy, safety, and tolerability of an extended-duration,
combined hormonal oral contraceptive pill (OCP) that reduces the estrogen exposure by …

BACKGROUND: This open-label, noncontrolled study assessed the long-term efficacy and
tolerability of the monophasic combined low-dose oral contraceptive (OC) ethinyl estradiol …

Background The progestogen component of oral contraceptives (OCs) has undergone
changes since it was recognized that their chemical structure can influence the spectrum of …

Hormonal contraceptives, in particular combined oral contraceptives (COCs), were designed
to avoid unintended pregnancy, with the fewest possible side effects and health risks. The …

The use of the term ''generation” to describe different formulations of combined oral
contraceptives (COCs) has no basis in pharmacology and creates confusion when used to …

Objectives To evaluate the effect on endocrine and metabolic parameters of a new
combined oral contraceptive (COC) containing estetrol (E4) and drospirenone (DRSP) …

Background: A novel estradiol-based combined oral contraceptive (COC) is currently
available in many countries worldwide, including Europe and the US. Based on previous …

A randomized, open-label, multicenter study was undertaken to compare the effects of oral
contraceptives (OC) containing 100 μg levonorgestrel (LNG)/20 μg ethinyl estradiol …

The strong hepatic estrogenic actions of ethinylestradiol (EE) are very likely to be the cause
of the cardiovascular morbidity related to the use of combined oral contraceptives (COCs) …

Estrogen content represents a tradeoff between cycle control and side effects, but few direct
comparisons of 20 and 30/35 μg preparations are available. To address this issue, we …